2Nakamura T, Ushiyama C, Hirokwa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin- 1 concentations in type2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol, 2001,21(6) :449 - 454.
3Kim SI, Hah DC,Lee HB. Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol,2000,11(1):80-87.
4Ota T, Takamura T, Ando E, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetdogia, 2003,46 (6): 843 - 851.
5Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well- controlled hypertension. Hypertension, 2002,40 ( 1 ): 67 - 73.
6Tesar V. Some important news in clinical nephrology in years 2003 - 2004. Vnitr Lek, 2004,50 (Suppl 1 ): 81 - 87.
7Aika M, Rabikin E, Sugivama S, et al. An HMGCOA reductase inhibitor,cerivas- tatin,suppresses growth of macrophage expressing matrix metalloproteinases, and tissue factor in vivo and in vitro. Circulation, 2001,103:276 - 283.
8Elisaf M, Mikhailidis DP. Statins and renal function. Angiology,2002,53(5) :493 - 502.
9EpsteinM, Campese VM. Pleiotropic effects of 3 - hydroxy-3- methylglutary coenzyme a reductase inhisitors on renal funtion. Am J Kidney Dis, 2005,45 (1): 2 - 14.
